Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3)

Carmelo Carlo-Stella, Pier Luigi Luigi Zinzani, Murali Janakiram, Vivian Dia, Xiaomin He, Annette Ervin-Haynes, Julien Depaus

Blood (2021) 138 (Supplement 1): 54.

https://doi.org/10.1182/blood-2021-147765

Published: 2021

Journal Articles

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Blood (2018) 131 (3): 301–310.

https://doi.org/10.1182/blood-2017-07-795047

Published: 2018

Includes: Supplemental data

Journal Articles

Final Analysis of Overall Survival from the First Trial

Blood (2016) 128 (22): 241.

https://doi.org/10.1182/blood.V128.22.241.241

Published: 2016

Journal Articles

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Thierry Facon, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch, Nathalie Meuleman, Mohamad Mohty, Wen-Ming Chen, Kihyun Kim, Elena Zamagni, Paula Rodriguez-Otero, MD PhD, William Renwick, Christian Rose, Adrian Tempescul, Antonio Palumbo, Shien Guo, Michael Sturniolo, Annette Ervin-Haynes, Jean-Paul Fermand

Blood (2015) 126 (23): 4239.

https://doi.org/10.1182/blood.V126.23.4239.4239

Published: 2015

Journal Articles

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Blood (2015) 126 (23): 4240.

https://doi.org/10.1182/blood.V126.23.4240.4240

Published: 2015

Journal Articles

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

Blood (2015) 126 (23): 730.

https://doi.org/10.1182/blood.V126.23.730.730

Published: 2015

Journal Articles

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

Blood (2014) 124 (21): 81.

https://doi.org/10.1182/blood.V124.21.81.81

Published: 2014

Journal Articles

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results

Blood (2014) 124 (21): 2112.

https://doi.org/10.1182/blood.V124.21.2112.2112

Published: 2014

Journal Articles

Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)

Katja Weisel, MD, Dan T. Vogl, Michel Delforge, MD PhF, Kevin Song, Meletios Dimopoulos, Jamie Cavenagh, Cyrille Hulin, Philippe Rodon, Bertrand Arnulf, Robin Foá, MD, Albert Oriol, MD, Shien Guo, Mara Silvia Monzini, Jason Van Oostendorp, Annette Ervin-Haynes, Thierry Facon, MD

Blood (2014) 124 (21): 1326.

https://doi.org/10.1182/blood.V124.21.1326.1326

Published: 2014

Journal Articles

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Blood (2014) 124 (21): 3458.

https://doi.org/10.1182/blood.V124.21.3458.3458

Published: 2014

Journal Articles

Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients

Blood (2014) 124 (21): 3452.

https://doi.org/10.1182/blood.V124.21.3452.3452

Published: 2014

Journal Articles

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Blood (2013) 122 (21): 2.

https://doi.org/10.1182/blood.V122.21.2.2

Published: 2013

Journal Articles

Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Pier Luigi Zinzani, MD, Julie M Vose, MD, MBA, Myron S. Czuczman, MD, Craig Reeder, MD, Corinne Haioun, MD, Jonathan Polikoff, MD, Herve Tilly, Dennis Pietronigro, Annette Ervin-Haynes, Ju Li, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2738.

https://doi.org/10.1182/blood.V120.21.2738.2738

Published: 2012

Journal Articles

Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).

Thomas E Witzig, MD, Julie M. Vose, M.D., Pier Luigi Zinzani, MD, Craig B. Reeder, MD, Rena Buckstein, MD, FRCPC, Jonathan Polikoff, MD, Pingshan Guo, Dennis Pietronigro, Annette Ervin-Haynes, Myron S Czuczman

Blood (2009) 114 (22): 1676.

https://doi.org/10.1182/blood.V114.22.1676.1676

Published: 2009

Journal Articles

Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.

Julie M. Vose, M.D., Thomas Habermann, Myron S Czuczman, Pier Luigi Zinzani, Craig B. Reeder, MD, Joseph Tuscano, MD, Izidore S Lossos, MD, Dennis Pietronigro, Annette Ervin-Haynes, Thomas Witzig

Blood (2009) 114 (22): 2699.

https://doi.org/10.1182/blood.V114.22.2699.2699

Published: 2009

Journal Articles

Antiproliferative Effects of Lenalidomide in Combination with Chemotherapeutic Agents in Lymphoma Cell Lines

Anita K Gandhi, Jian Kang, Lori Capone, Ling-Hua Zhang, Blake Bartlett, Dennis Pietronegro, Annette Ervin-Haynes, Peter H Schafer

Blood (2008) 112 (11): 4990.

https://doi.org/10.1182/blood.V112.11.4990.4990

Published: 2008

Journal Articles

The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003).

Craig B. Reeder, MD, T.E. Witzig, Julie M. Vose, Pier Luigi Zinzani, MD, Rena Buckstein, MD, FRCPC, Corinne Haioun, Reda Bouabdallah, MD, Jonathan Polikoff, MD, Pingshan Guo, Annette Ervin-Haynes, Dennis Pietronigro, Jerome B. Zeldis, MD, Myron S. Czuczman, MD

Blood (2008) 112 (11): 1560.

https://doi.org/10.1182/blood.V112.11.1560.1560

Published: 2008

Journal Articles

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Diffuse Large-B-Cell Lymphoma: Results of An International Study (NHL-003)

Myron S. Czuczman, MD, Julie M. Vose, MD, Pier Luigi Zinzani, MD, Craig B. Reeder, MD, Rena Buckstein, MD, FRCPC, Corinne Haioun, Reda Bouabdallah, MD, Jonathan Polikoff, MD, Pingshan Guo, Annette Ervin-Haynes, Dennis Pietronigro, Jerome B. Zeldis, MD, Thomas E. Witzig

Blood (2008) 112 (11): 268.

https://doi.org/10.1182/blood.V112.11.268.268

Published: 2008

Journal Articles

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Julie M. Vose, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Izidore S. Lossos, MD, Annette Ervin-Haynes, DO, Kenichi Takeshita, MD, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2570.

https://doi.org/10.1182/blood.V110.11.2570.2570

Published: 2007

Journal Articles

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Thomas E. Witzig, MD, Craig B. Reeder, MD, Jonathan Polikoff, MD, Naveed M. Chowhan, MD, Isaac Esseessee, MD, Richard Greenberg, MD, Hermant Patel, MD, Davood Vafai, MD, Peter H. Wiernik, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Myron Czuczman, MD

Blood (2007) 110 (11): 2572.

https://doi.org/10.1182/blood.V110.11.2572.2572

Published: 2007

NARROW

Planned Interim Analysis of a Phase 2 Study of Loncastuximab Tesirine Plus Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma (LOTIS-3)

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Final Analysis of Overall Survival from the First Trial

A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial

Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results

Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM)

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients

Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)

Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).

Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.

Antiproliferative Effects of Lenalidomide in Combination with Chemotherapeutic Agents in Lymphoma Cell Lines

The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003).

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Diffuse Large-B-Cell Lymphoma: Results of An International Study (NHL-003)

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only